RU2007132852A - Продукт комбинации о-десметилвенлафаксина и базедоксифена и его применение - Google Patents
Продукт комбинации о-десметилвенлафаксина и базедоксифена и его применение Download PDFInfo
- Publication number
- RU2007132852A RU2007132852A RU2007132852/15A RU2007132852A RU2007132852A RU 2007132852 A RU2007132852 A RU 2007132852A RU 2007132852/15 A RU2007132852/15 A RU 2007132852/15A RU 2007132852 A RU2007132852 A RU 2007132852A RU 2007132852 A RU2007132852 A RU 2007132852A
- Authority
- RU
- Russia
- Prior art keywords
- bazedoxifene
- product according
- pharmaceutically acceptable
- acceptable salt
- desmethylvenlafaxine
- Prior art date
Links
- 239000013066 combination product Substances 0.000 title claims 4
- 229940127555 combination product Drugs 0.000 title claims 4
- 229960000817 bazedoxifene Drugs 0.000 claims abstract 22
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 claims abstract 22
- 150000003839 salts Chemical class 0.000 claims abstract 19
- ORUUBRMVQCKYHB-UHFFFAOYSA-N butanedioic acid;4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol Chemical compound OC(=O)CCC(O)=O.C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 ORUUBRMVQCKYHB-UHFFFAOYSA-N 0.000 claims abstract 13
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 claims abstract 11
- 239000010410 layer Substances 0.000 claims abstract 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract 7
- OMZAMQFQZMUNTP-UHFFFAOYSA-N acetic acid;1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol Chemical compound CC(O)=O.C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 OMZAMQFQZMUNTP-UHFFFAOYSA-N 0.000 claims abstract 7
- 229960003713 bazedoxifene acetate Drugs 0.000 claims abstract 7
- 239000002775 capsule Substances 0.000 claims abstract 7
- 229960004981 desvenlafaxine succinate Drugs 0.000 claims abstract 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract 7
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract 5
- 239000011247 coating layer Substances 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 4
- 239000012458 free base Substances 0.000 claims abstract 4
- 239000000454 talc Substances 0.000 claims abstract 3
- 229910052623 talc Inorganic materials 0.000 claims abstract 3
- 235000012222 talc Nutrition 0.000 claims abstract 2
- 239000000047 product Substances 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 208000019901 Anxiety disease Diseases 0.000 claims 5
- 206010003694 Atrophy Diseases 0.000 claims 5
- 208000001640 Fibromyalgia Diseases 0.000 claims 5
- 208000033830 Hot Flashes Diseases 0.000 claims 5
- 206010060800 Hot flush Diseases 0.000 claims 5
- 208000001132 Osteoporosis Diseases 0.000 claims 5
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 5
- 230000036506 anxiety Effects 0.000 claims 5
- 230000037444 atrophy Effects 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229940011871 estrogen Drugs 0.000 claims 5
- 239000000262 estrogen Substances 0.000 claims 5
- 230000000968 intestinal effect Effects 0.000 claims 5
- 230000035945 sensitivity Effects 0.000 claims 5
- 239000007962 solid dispersion Substances 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 4
- 239000008187 granular material Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940032147 starch Drugs 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66690205P | 2005-03-31 | 2005-03-31 | |
| US60/666,902 | 2005-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007132852A true RU2007132852A (ru) | 2009-05-10 |
Family
ID=36716648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007132852/15A RU2007132852A (ru) | 2005-03-31 | 2006-03-22 | Продукт комбинации о-десметилвенлафаксина и базедоксифена и его применение |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20060223791A1 (enExample) |
| EP (1) | EP1863464B1 (enExample) |
| JP (1) | JP2008534592A (enExample) |
| KR (1) | KR20070116607A (enExample) |
| CN (1) | CN101151026A (enExample) |
| AR (1) | AR052955A1 (enExample) |
| AT (1) | ATE447943T1 (enExample) |
| AU (1) | AU2006229869A1 (enExample) |
| BR (1) | BRPI0608754A2 (enExample) |
| CA (1) | CA2601898A1 (enExample) |
| CR (1) | CR9392A (enExample) |
| DE (1) | DE602006010343D1 (enExample) |
| ES (1) | ES2335919T3 (enExample) |
| GT (1) | GT200600127A (enExample) |
| IL (1) | IL185864A0 (enExample) |
| MX (1) | MX2007012167A (enExample) |
| NO (1) | NO20074559L (enExample) |
| PE (1) | PE20061336A1 (enExample) |
| RU (1) | RU2007132852A (enExample) |
| TW (1) | TW200719883A (enExample) |
| WO (1) | WO2006104791A1 (enExample) |
| ZA (1) | ZA200708323B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1942177B (zh) * | 2004-04-08 | 2011-05-25 | 惠氏公司 | 醋酸巴泽多昔芬固体分散剂型 |
| AR057662A1 (es) * | 2005-07-15 | 2007-12-12 | Wyeth Corp | Inhibidor de la recaptacion doble de serotonina y norepinefrina con alta selectividad y uso del mismo |
| US7687520B2 (en) * | 2005-07-15 | 2010-03-30 | Wyeth Llc | Serotonin and norepinephrine reuptake inhibitors and uses thereof |
| US7595340B2 (en) * | 2005-07-15 | 2009-09-29 | Wyeth | Serotonin and norepinephrine reuptake inhibitor and uses thereof |
| TW200806282A (en) * | 2006-05-05 | 2008-02-01 | Wyeth Corp | Solid dosage formulations |
| CA2670544A1 (en) * | 2006-11-29 | 2008-06-05 | Wyeth | Estrogen/ serm and estrogen/ progestin bi-layer tablets |
| IN2010CN00695A (enExample) * | 2007-07-12 | 2010-08-27 | Reddys Lab Ltd Dr | |
| CZ302358B6 (cs) * | 2007-07-25 | 2011-03-30 | Zentiva, A. S. | Nové soli bazedoxifenu |
| CN101584696A (zh) * | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | 包含喹唑啉衍生物的组合物及制备方法、用途 |
| US9408814B2 (en) | 2010-03-31 | 2016-08-09 | Wockhardt Limited | Modified release dosage form comprising desvenlafaxine or salts thereof |
| EP2407467A1 (de) * | 2010-07-14 | 2012-01-18 | Sandoz Ag | Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure |
| MX2013011884A (es) * | 2011-04-12 | 2013-11-21 | Lupin Ltd | Composiciones farmaceuticas de liberacion modificada de desvenlafaxina. |
| WO2013182170A1 (en) * | 2012-06-07 | 2013-12-12 | Zentiva, K. S. | Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate |
| CN112754999A (zh) * | 2021-01-23 | 2021-05-07 | 郑州泰丰制药有限公司 | 一种醋酸巴多昔芬组合物及醋酸巴多昔芬薄膜衣片制备方法 |
| CN113368075A (zh) * | 2021-06-29 | 2021-09-10 | 郑州泰丰制药有限公司 | 一种醋酸巴多昔芬片及其制备方法 |
| CN120531695A (zh) * | 2023-08-03 | 2025-08-26 | 常山凯捷健生物药物研发（河北）有限公司 | 一种包含取代的吲哚-5-酚衍生物的药物组合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
| US5998402A (en) * | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| US6479535B1 (en) * | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
| HK1052877A1 (zh) * | 2000-07-06 | 2003-10-03 | Wyeth | Ssri与雌激素剂之组合 |
| AR029538A1 (es) * | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
| NZ539791A (en) * | 2001-02-12 | 2006-11-30 | Wyeth Corp | Novel succinate salt of o-desmethyl-venlafaxine |
| WO2003105834A1 (en) * | 2002-06-13 | 2003-12-24 | Wyeth | Bazedoxifene treatment regimens |
| AU2005212166A1 (en) * | 2004-02-06 | 2005-08-25 | Wyeth | Multiparticulate O-desmethylvenlafaxine salts and uses thereof |
| AR054833A1 (es) * | 2005-07-15 | 2007-07-18 | Wyeth Corp | Formas de dosificacion de liberacion retardada oral altamemte biodisponibles de succinato de o-desmetilvenlafaxina |
-
2006
- 2006-03-22 CA CA002601898A patent/CA2601898A1/en not_active Abandoned
- 2006-03-22 AU AU2006229869A patent/AU2006229869A1/en not_active Abandoned
- 2006-03-22 US US11/386,420 patent/US20060223791A1/en not_active Abandoned
- 2006-03-22 BR BRPI0608754-0A patent/BRPI0608754A2/pt not_active IP Right Cessation
- 2006-03-22 RU RU2007132852/15A patent/RU2007132852A/ru not_active Application Discontinuation
- 2006-03-22 MX MX2007012167A patent/MX2007012167A/es active IP Right Grant
- 2006-03-22 ES ES06739215T patent/ES2335919T3/es active Active
- 2006-03-22 EP EP06739215A patent/EP1863464B1/en not_active Not-in-force
- 2006-03-22 WO PCT/US2006/010335 patent/WO2006104791A1/en not_active Ceased
- 2006-03-22 KR KR1020077021609A patent/KR20070116607A/ko not_active Withdrawn
- 2006-03-22 CN CNA2006800102992A patent/CN101151026A/zh active Pending
- 2006-03-22 AT AT06739215T patent/ATE447943T1/de not_active IP Right Cessation
- 2006-03-22 DE DE602006010343T patent/DE602006010343D1/de active Active
- 2006-03-22 JP JP2008504152A patent/JP2008534592A/ja not_active Withdrawn
- 2006-03-27 TW TW095110550A patent/TW200719883A/zh unknown
- 2006-03-29 GT GT200600127A patent/GT200600127A/es unknown
- 2006-03-29 AR ARP060101219A patent/AR052955A1/es unknown
- 2006-03-29 PE PE2006000349A patent/PE20061336A1/es not_active Application Discontinuation
-
2007
- 2007-09-10 IL IL185864A patent/IL185864A0/en unknown
- 2007-09-10 NO NO20074559A patent/NO20074559L/no not_active Application Discontinuation
- 2007-09-24 CR CR9392A patent/CR9392A/es not_active Application Discontinuation
- 2007-09-28 ZA ZA200708323A patent/ZA200708323B/xx unknown
-
2010
- 2010-04-30 US US12/771,350 patent/US20100221445A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007012167A (es) | 2007-11-22 |
| EP1863464B1 (en) | 2009-11-11 |
| IL185864A0 (en) | 2008-01-06 |
| PE20061336A1 (es) | 2006-12-27 |
| US20100221445A1 (en) | 2010-09-02 |
| BRPI0608754A2 (pt) | 2010-01-26 |
| US20060223791A1 (en) | 2006-10-05 |
| GT200600127A (es) | 2006-11-29 |
| CR9392A (es) | 2008-02-20 |
| KR20070116607A (ko) | 2007-12-10 |
| ES2335919T3 (es) | 2010-04-06 |
| CN101151026A (zh) | 2008-03-26 |
| WO2006104791A1 (en) | 2006-10-05 |
| TW200719883A (en) | 2007-06-01 |
| ZA200708323B (en) | 2010-03-31 |
| DE602006010343D1 (de) | 2009-12-24 |
| NO20074559L (no) | 2007-12-27 |
| ATE447943T1 (de) | 2009-11-15 |
| JP2008534592A (ja) | 2008-08-28 |
| AU2006229869A1 (en) | 2006-10-05 |
| EP1863464A1 (en) | 2007-12-12 |
| CA2601898A1 (en) | 2006-10-05 |
| AR052955A1 (es) | 2007-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007132852A (ru) | Продукт комбинации о-десметилвенлафаксина и базедоксифена и его применение | |
| US9901568B2 (en) | Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound | |
| JP5933258B2 (ja) | ゾニサミドおよびアカンプロセートを用いるアルツハイマー病および関連障害の処置のための併用組成物 | |
| JP5656883B2 (ja) | エスゾピクロンを用いる治療方法 | |
| CN120040398A (zh) | 用于精神障碍或精神增强的有利苯并呋喃组合物 | |
| CN116096715A (zh) | 用于精神障碍或精神增强的有益苯并噻吩组合物 | |
| CA2829200C (en) | Methods and compositions for treating depression using cyclobenzaprine | |
| JP2008534592A5 (enExample) | ||
| MX2008000249A (es) | Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos. | |
| CA2614244A1 (en) | Combinations of eszopiclone and an antidepressant | |
| RU2006135124A (ru) | Фармацевтические композиции толперизона контролируемого высвобождения, предназначенные для перорального введения | |
| US7465729B2 (en) | Methods of treatment of menopause and perimenopause using eszopiclone | |
| JP2013199506A (ja) | 処置方法 | |
| KR20200128437A (ko) | 치료 방법 | |
| US20160346249A1 (en) | Use of amitifadine, (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in methods and compositions with enhanced efficacy and reduced metabolic side effects and toxicity for treatment of depression and other central nervous system disorders and conditions affected by monoamine neurotransmitters | |
| CN110251473A (zh) | 羟哌吡酮口服缓释制剂 | |
| EP2830641B1 (en) | New valerian extracts and uses thereof | |
| AU2011202540B2 (en) | Methods of treatment using eszopiclone | |
| CN101596195A (zh) | 降低血压的口服药物组合物 | |
| CA2425910A1 (en) | Treatment and prevention of gastrointestinal disease using antagonists or partial agonists of 5ht1a receptors | |
| CA2912302A1 (en) | Compositions and methods for treating cardiometabolic diseases and disorders | |
| TH1901003565A (th) | รูปที่ใช้โดสทางปากที่มีการปลดปล่อยในทันทีและที่ถูกดัดแปรของทีไบพีเนม พิโวซิลชนิดใหม่ | |
| NZ714294B2 (en) | Methods And Compositions For Treating Depression Using Cyclobenzaprine | |
| HK1073779B (en) | The use of darifenacin and the salt thereof | |
| KR20160146872A (ko) | 이명 환자의 치료용 약제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20110516 |